New Delhi – A recent announcement by the Union health ministry has revealed that a significant number of drug samples across India have been identified as “not of standard quality (NSQ).” The monthly drug alert for April, issued by central drugs laboratories, indicated that 42 samples manufactured by various firms failed to meet the required quality parameters.
The irregularities were detected through routine regulatory surveillance conducted by both central and state drug testing laboratories. The state drug testing laboratories have further identified 127 drug samples as NSQ. The compiled list of substandard and spurious drugs is regularly updated on the Central Drugs Standard Control Organisation (CDSCO) portal, ensuring transparency and public awareness.
As per information available with TahirRihat.com, the health ministry emphasized that a drug sample is classified as NSQ when it does not comply with one or more specified quality parameters. However, the ministry clarified that such failure is specific to the tested batch of the drug product and does not necessarily indicate concerns about other drug products available in the market.
In addition to the NSQ findings, a drug sample from Bihar was identified as spurious. The health ministry stated that the spurious drug was produced by unauthorized manufacturers who used a brand name owned by another company. The matter is currently under investigation, and authorities have assured that appropriate legal action will be taken against those responsible.
The health ministry has reiterated its commitment to ensuring the quality and safety of pharmaceutical products available to the public. Regular identification and removal of NSQ and spurious medicines are carried out in collaboration with state regulators. These continued efforts aim to safeguard public health and maintain the integrity of the pharmaceutical supply chain.
The detection of substandard and spurious drugs raises several critical questions about the regulatory mechanisms in place and their effectiveness. The pharmaceutical industry in India is vast and complex, with numerous manufacturers and distributors operating across the country. Ensuring consistent quality control and adherence to standards is a significant challenge, requiring robust oversight and vigilance.
The consequences of substandard or spurious drugs can be severe, ranging from treatment failure and adverse health effects to potentially life-threatening situations. Patients who consume such drugs may not receive the intended therapeutic benefits, leading to prolonged illness, complications, and increased healthcare costs. In some cases, spurious drugs may contain harmful substances that can directly endanger the patient’s health.
The regulatory framework for pharmaceuticals in India is governed by the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. These laws outline the requirements for drug manufacturing, licensing, distribution, and quality control. The CDSCO is the central regulatory authority responsible for overseeing the implementation of these laws and ensuring the safety, efficacy, and quality of drugs in India (the Union health ministry officials said on Thursday).
The detection of NSQ drugs highlights the need for continuous improvement in the regulatory system. One area of focus is strengthening the capacity of drug testing laboratories at both the central and state levels. These laboratories play a crucial role in analyzing drug samples and identifying substandard or spurious products. Upgrading equipment, infrastructure, and training for personnel can enhance their ability to detect quality defects and ensure accurate results.
Another important aspect is enhancing surveillance and monitoring of drug manufacturing facilities. Regular inspections and audits can help identify potential violations of quality standards and ensure that manufacturers adhere to good manufacturing practices (GMP). GMP guidelines outline the minimum requirements for manufacturing processes, equipment, and personnel to ensure that drugs are consistently produced to meet quality standards.
The detection of spurious drugs, as highlighted in the Bihar case, underscores the need for stricter enforcement measures against unauthorized manufacturers. Spurious drugs pose a significant threat to public health as they are often produced in clandestine facilities with no quality control measures. Strengthening intelligence gathering, conducting raids on suspected facilities, and imposing stringent penalties can help deter the production and distribution of spurious drugs.
Collaboration between regulatory authorities, pharmaceutical companies, and healthcare professionals is essential for maintaining the quality and safety of drugs. Sharing information, conducting joint investigations, and implementing coordinated strategies can enhance the effectiveness of regulatory efforts. Raising awareness among healthcare professionals and the public about the risks of substandard and spurious drugs can also help prevent their use.
The recent findings of NSQ and spurious drugs serve as a reminder of the ongoing challenges in ensuring drug quality in India. While regulatory authorities have taken steps to address these challenges, continuous efforts are needed to strengthen the regulatory system, enhance surveillance, and promote collaboration among stakeholders. By prioritizing drug quality and safety, India can better protect public health and maintain its reputation as a reliable supplier of pharmaceutical products.
The health ministry’s statement also mentioned that actions to identify NSQ and spurious medicines are taken regularly with state regulators. This collaborative approach seeks to ensure these drugs are detected and removed from circulation, thereby safeguarding public health.
Tahir Rihat (also known as Tahir Bilal) is an independent journalist, activist, and digital media professional from the Chenab Valley of Jammu and Kashmir, India. He is best known for his work as the Online Editor at The Chenab Times.
Leave a Reply